JP2007510671A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007510671A5 JP2007510671A5 JP2006538531A JP2006538531A JP2007510671A5 JP 2007510671 A5 JP2007510671 A5 JP 2007510671A5 JP 2006538531 A JP2006538531 A JP 2006538531A JP 2006538531 A JP2006538531 A JP 2006538531A JP 2007510671 A5 JP2007510671 A5 JP 2007510671A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocycle
- aryl
- pharmaceutical composition
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCCC(C1=C2*)NN=C1c1ccccc1C2=O Chemical compound CCCC(C1=C2*)NN=C1c1ccccc1C2=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51860103P | 2003-11-06 | 2003-11-06 | |
| PCT/US2004/037084 WO2005046594A2 (en) | 2003-11-06 | 2004-11-04 | Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007510671A JP2007510671A (ja) | 2007-04-26 |
| JP2007510671A5 true JP2007510671A5 (https=) | 2007-09-20 |
Family
ID=34590281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538531A Pending JP2007510671A (ja) | 2003-11-06 | 2004-11-04 | アスベスト関連疾患および障害の治療および管理のための、ｊｎｋ阻害剤の使用方法およびそれを含む組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070270448A1 (https=) |
| EP (1) | EP1684690A4 (https=) |
| JP (1) | JP2007510671A (https=) |
| KR (1) | KR20060124610A (https=) |
| CN (1) | CN1901903A (https=) |
| AU (1) | AU2004288715A1 (https=) |
| BR (1) | BRPI0416266A (https=) |
| CA (1) | CA2544591A1 (https=) |
| IL (1) | IL175428A0 (https=) |
| WO (1) | WO2005046594A2 (https=) |
| ZA (1) | ZA200603719B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010009166A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Oxindolyl inhibitor compounds |
| CA2729909A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Imidazolyl pyrimidine inhibitor compounds |
| US8124764B2 (en) | 2008-07-14 | 2012-02-28 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitor compounds |
| CN102123987A (zh) | 2008-07-28 | 2011-07-13 | 吉里德科学公司 | 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物 |
| US20100183633A1 (en) * | 2008-12-04 | 2010-07-22 | University Of Massachusetts | Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition |
| US8283357B2 (en) | 2009-06-08 | 2012-10-09 | Gilead Sciences, Inc. | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds |
| KR20120031170A (ko) | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물 |
| CA3032972A1 (en) * | 2016-08-19 | 2018-02-22 | Memorial Sloan-Kettering Cancer Center | Methods of differentiating stem cells into endoderm |
| CN113698408B (zh) * | 2020-05-22 | 2025-07-25 | 武汉朗来科技发展有限公司 | Jnk抑制剂、其药物组合物和用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3095415A (en) * | 1958-05-30 | 1963-06-25 | Ciba Ltd | Anthraquinone dyestuffs containing a 2-chloro, 4-hydroxy (lower) alkylamino, triazinylamino group |
| CH428043A (fr) * | 1965-08-16 | 1967-01-15 | Sandoz Ag | Procédé de fabrication de colorants de dispersion isothiazolantroniques |
| US3541110A (en) * | 1967-01-20 | 1970-11-17 | American Home Prod | Indazole-5-sulfonamides |
| JPS63184364A (ja) * | 1987-01-27 | 1988-07-29 | Toshiba Corp | 半導体装置の製造方法 |
| CN1137680C (zh) * | 1995-09-19 | 2004-02-11 | 藤泽药品工业株式会社 | 气雾剂组合物 |
| GB9622363D0 (en) * | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
| AU6870098A (en) * | 1997-03-31 | 1998-10-22 | Du Pont Merck Pharmaceutical Company, The | Indazoles of cyclic ureas useful as hiv protease inhibitors |
| US7507705B2 (en) * | 1997-10-02 | 2009-03-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
| US20040072888A1 (en) * | 1999-08-19 | 2004-04-15 | Bennett Brydon L. | Methods for treating inflammatory conditions or inhibiting JNK |
| KR20080028516A (ko) * | 1999-08-19 | 2008-03-31 | 시그널 파머슈티컬스 인크 | Ｊｎｋ억제제로서의 피라졸로안트론과 그 유도체 및 이를함유하는 조성물 |
| YU54202A (sh) * | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| US7211594B2 (en) * | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
| US7429599B2 (en) * | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| US7122544B2 (en) * | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| BR0116452A (pt) * | 2000-12-21 | 2003-09-30 | Glaxo Group Ltd | Composto, composição farmacêutica, uso de um composto |
| US6987184B2 (en) * | 2001-02-15 | 2006-01-17 | Signal Pharmaceuticals, Llc | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related |
| WO2003075917A1 (en) * | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US20060004043A1 (en) * | 2003-11-19 | 2006-01-05 | Bhagwat Shripad S | Indazole compounds and methods of use thereof |
-
2004
- 2004-11-04 KR KR1020067011021A patent/KR20060124610A/ko not_active Withdrawn
- 2004-11-04 EP EP04800843A patent/EP1684690A4/en not_active Withdrawn
- 2004-11-04 CN CNA2004800400028A patent/CN1901903A/zh active Pending
- 2004-11-04 CA CA002544591A patent/CA2544591A1/en not_active Abandoned
- 2004-11-04 AU AU2004288715A patent/AU2004288715A1/en not_active Abandoned
- 2004-11-04 JP JP2006538531A patent/JP2007510671A/ja active Pending
- 2004-11-04 US US10/578,809 patent/US20070270448A1/en not_active Abandoned
- 2004-11-04 WO PCT/US2004/037084 patent/WO2005046594A2/en not_active Ceased
- 2004-11-04 ZA ZA200603719A patent/ZA200603719B/en unknown
- 2004-11-04 BR BRPI0416266-8A patent/BRPI0416266A/pt not_active IP Right Cessation
-
2006
- 2006-05-04 IL IL175428A patent/IL175428A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533748A5 (https=) | ||
| CN111886006B (zh) | 治疗肥大细胞增多症的组合疗法 | |
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| US20090209496A1 (en) | Methods and compositions for enhancing the efficacy of rtk inhibitors | |
| JP2022520061A5 (https=) | ||
| JP2020516621A5 (https=) | ||
| DE10178132T1 (de) | Antivirales Mittel | |
| RU2357734C2 (ru) | КОМБИНАЦИЯ АНТАГОНИСТА РЕЦЕПТОРА mGluR2 И ИНГИБИТОРА ФЕРМЕНТА AChE ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И/ИЛИ ХРОНИЧЕСКИХ НЕВРОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ | |
| JP2016502544A5 (https=) | ||
| JP2001517250A (ja) | ナフタレンスルホン酸誘導体を含有する相乗作用抗腫瘍組成物 | |
| JP2007510671A5 (https=) | ||
| JP2019507111A5 (https=) | ||
| WO2013096684A1 (en) | Hypoxia activated prodrugs and mtor inhibitors for treating cancer | |
| JP2021522197A5 (https=) | ||
| JPH0656698A (ja) | 潰瘍胃腸症状の予防もしくは治療用組成物 | |
| JP2019524852A5 (https=) | ||
| JP2007500201A (ja) | エクチナサイジン−７４３と白金抗腫瘍化合物との併用 | |
| CZ302451B6 (cs) | Protirakovinová farmaceutická kombinace | |
| JP2023507610A5 (https=) | ||
| AU2006236812A1 (en) | Combinations, methods and compositions for treating cancer | |
| EP4591940A3 (en) | Deoxy- cytidine derivatives for use in cancer therapies | |
| JP2019513812A5 (https=) | ||
| HUP0401153A2 (hu) | Epothilone-származékokat tartalmazó kombinációk és azok gyógyszerészeti felhasználása | |
| JP2007500240A5 (https=) | ||
| JP2007500240A (ja) | Ａｂｔ−７５１による持続投与レジメン |